Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan
(NASDAQ: VIRX) Delayed: 0.08 --0 (-0%)
Previous Close $0.08    52 Week High $ 
Open $0.08    52 Week Low $ 
Day High $0.08    P/E N/A 
Day Low $0.08    EPS $ 
Volume 617